Cargando…

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants

OBJECTIVES: Inflammation is involved in the pathogenesis of depression. A few cross-sectional population-based studies have found that depression is associated with increased levels of inflammatory markers. Soluble urokinase plasminogen activation receptor (suPAR) is known to be a stable marker for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haastrup, Eva, Grau, Katrine, Eugen-Olsen, Jesper, Thorball, Christian, Kessing, Lars Vedel, Ullum, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203805/ https://www.ncbi.nlm.nih.gov/pubmed/25329298 http://dx.doi.org/10.1371/journal.pone.0110555

Ejemplares similares

Risk Factors Associated with Serum Levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator Receptor in a General Population
por: Haupt, Thomas H, et al.
Publicado: (2014)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
por: Dowsett, Joseph, et al.
Publicado: (2021)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis
por: Butt, Sheraz, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department
por: Stauning, Marius Ahm, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease
por: Iversen, Esben, et al.
Publicado: (2022)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2016)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study)
por: Kruger, Ruan, et al.
Publicado: (2014)

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy
por: Schultz, Martin, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events
por: Eapen, Danny J., et al.
Publicado: (2014)

Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity
por: Can, Ummugulsum, et al.
Publicado: (2017)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study
por: Kofoed, Kristian, et al.
Publicado: (2007)

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study*
por: Rasmussen, Line J. H., et al.
Publicado: (2018)

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
por: Sommerer, Claudia, et al.
Publicado: (2019)

Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD
por: Sommerer, Claudia, et al.
Publicado: (2023)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV‐1‐infected patients: a nested case‐control study
por: Rasmussen, LJH, et al.
Publicado: (2015)

Soluble Urokinase Plasminogen Activator Receptor Levels in Tuberculosis Patients at High Risk for Multidrug Resistance
por: Mardining Raras, Tri Yudani, et al.
Publicado: (2012)

Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness
por: Cyrille, Nicole B., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5mo0ondgobbtfpl9knk1vqkfo3